Insider Selling: Humacyte, Inc. (NASDAQ:HUMA) CEO Sells 811,172 Shares of Stock

Humacyte, Inc. (NASDAQ:HUMA) CEO Laura E. Niklason sold 811,172 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.44, for a total value of $3,601,603.68. Following the completion of the sale, the chief executive officer now owns 2,419,712 shares in the company, valued at approximately $10,743,521.28. The trade was a 25.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Humacyte Trading Down 0.2 %

HUMA stock traded down $0.01 during midday trading on Wednesday, hitting $4.41. The company had a trading volume of 2,094,875 shares, compared to its average volume of 2,412,612. The stock has a market cap of $555.04 million, a price-to-earnings ratio of -3.30 and a beta of 1.47. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61. The stock’s 50 day moving average price is $5.38 and its 200 day moving average price is $6.20. Humacyte, Inc. has a 52 week low of $2.43 and a 52 week high of $9.97.

Hedge Funds Weigh In On Humacyte

Several hedge funds and other institutional investors have recently modified their holdings of the company. nVerses Capital LLC bought a new position in Humacyte during the 2nd quarter valued at approximately $28,000. Concurrent Investment Advisors LLC bought a new position in Humacyte in the third quarter worth $75,000. Principal Financial Group Inc. bought a new stake in shares of Humacyte during the 2nd quarter valued at $83,000. FORA Capital LLC bought a new position in shares of Humacyte in the 3rd quarter worth about $96,000. Finally, Insigneo Advisory Services LLC purchased a new position in Humacyte during the 3rd quarter valued at about $109,000. 44.71% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

HUMA has been the subject of a number of recent analyst reports. TD Cowen reaffirmed a “buy” rating and set a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Humacyte in a research report on Wednesday, November 13th. Benchmark restated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a research report on Thursday, October 10th. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. Finally, BTIG Research reaffirmed a “buy” rating and set a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Humacyte has a consensus rating of “Buy” and an average target price of $11.00.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.